Ilya Pharma, a clinical stage biopharma company, today announced that multiple dosing in the Phase I trial for its lead candidate ILP100 has already commenced. Initial single dosing in three cohorts has been completed in 4 months which represents rapid progress. ILP100 is the first drug based on genetically engineered lactic acid bacteria to be approved to enter trials as a topical treatment. The Company is now preparing for the phase II clinical developments and in response, Ilya has strengthened its clinical development team with two key senior appointments with key experience: ex-Renovo / Smith & Nephew Wound Management David Fairlamb as expert advisor and ex Novartis Andreas Fasth as Head of Clinical Developments.
Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31
Evelina Vågesjö and the achievements of Ilya Pharma recognised by MIT Tech Review Innovators under 35
Ilya Pharma will present new data and development plans for our ILP100 candidate at IBD Innovate, organised by Chrones and Colitis Foundation, NYC 4th of December
IBD INNOVATE: Product Development for Crohn’s & Colitis™. The Symposium is co-hosted by Eli Lilly and Celgene.